在人才与传承体系上，公司着力搭建老中青相结合的传承人队伍，不仅培育了国家级非遗传承人、大国 工匠等多层次技术人才，更与国医大师合作共建传承创新工作室，确保中医文化和技艺的有效传承。在 此基础上，公司系统梳理中药药典和传统方剂，深化中药正源研究，为后续的守正创新奠定了坚实基 础。 中国上市公司协会联合中国基金报等媒体，开展"我在'十四五'这五年，上市公司在行动"主题宣传活 动。日前，记者走进重庆太极实业（600667）（集团）股份有限公司（以下简称太极集团（600129）或 公司，股票代码：600129.SH），多方位了解"十四五"期间太极集团在推动中医药产业高质量发展中的 创新与坚守。 关于"出新"，太极集团逐年加大研发投入。2025年上半年，公司研发投入1.37亿元，同比增长18.12%。 战略引领：锚定"世界一流的中药企业"愿景 "十四五"期间，太极集团提出"做世界一流的中药企业"的企业愿景，确立"关爱生命呵护健康"的企业理 念，心怀"国药泽华夏，太极济苍生"的企业使命。 "在战略方向上，公司聚焦'4+1'重点产品管线，加大中药大品种二次开发及中药创新药研发，并通过全 产业链数字化转型升级，不断提升现代中 ...

中国上市公司协会联合中国基金报等媒体，开展 " 我在 ' 十四五 ' 这五年，上市公司在行动 " 主题宣传活动。日前，记者走进重庆太极实 业（集团）股份有限公司（以下简称太极集团或公司，股票代码： 600129.SH ），多方位了解 " 十四五 " 期间太极集团在推动中医药产 业高质量发展中的创新与坚守。 见习记者 荧墨 战略引领：锚定 " 世界一流的中药企业 " 愿景 " 十四五 " 期间，太极集团提出 " 做世界一流的中药企业 " 的企业愿 景，确立 " 关爱生命 呵护健康 " 的企业理念，心怀 " 国药泽华 夏， 太极济苍生 " 的企业使命。 " 在战略方向上，公司聚焦 '4+1' 重点产品管线，加大中药大品种二次开发及中药创新药研发，并通过全产业链数字化转型升级，不断提 升现代中药智能制造水平。 " 太极集团向记者表示， 在中医药传承创新方面，太极集团树立了 " 正源出新 精益求精 " 的企业核心价值 观，提出 " 三源三新 " 理念。 " 三源三新 " 即正中华文明之源、正中医文化之源、正中药本草之源，创新产品形态、创新产出业态、创新产业生态，推动中医药现代化 和国际化。 关于 " 正源 " ，太极 ...

Investment Rating - The report assigns an "Accumulate" rating for the company [4] Core Viewpoints - The company benefits from the revival of traditional Chinese medicine, with stable core business and a strong moat for its "Shuanghuanglian" product series, which is expected to benefit from differentiation, segmentation, and upgrading trends [3] - The new controlling shareholder has strong background and capabilities, which will enhance resource matching, management models, and development strategies, promoting long-term and sustainable growth [3] Financial Performance Summary - Revenue is projected to reach CNY 2,070 million in 2023, with a year-on-year growth rate of 5.6%, followed by a decline of 6.2% in 2024, and then a recovery with growth rates of 9.8%, 10.1%, and 10.0% in the subsequent years [1] - Net profit attributable to shareholders is expected to grow significantly from CNY 44 million in 2023 to CNY 116 million by 2027, reflecting a year-on-year growth rate of 160.3% in 2023 and steady growth thereafter [1] - The company's return on equity (ROE) is projected to improve from 2.8% in 2023 to 6.4% by 2027 [1] Business Segments Summary - The company has a diversified business layout, including drug manufacturing and research services, with a focus on traditional Chinese medicine [12] - The "Shuanghuanglian" oral liquid is a leading product, capturing over 30% market share in 2023, with sales exceeding CNY 700 million [2] - The company’s CRO (Contract Research Organization) business is expected to experience growth due to favorable regulatory changes and increased demand for drug research services [2][3] Market Position and Competitive Landscape - The company ranks third in the market for cold medicine in public medical institutions, with a significant presence in the hospital sector [38] - The recent national centralized procurement is expected to enhance the company's market position, as the selected prices for its products remain stable, indicating limited impact on pricing [2][59]